

## Company Overview

SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas.

## The World Health Organization Recognizes New Antifungal Class by Granting "ibrexafungerp" to SCYNEXIS as the International Non-Proprietary Name for SCY-078

Jul 18 2018, 8:05 AM EDT

## SCYNEXIS Reports Positive Results from Phase 2b Dose-Finding Study of Oral SCY-078 in Vulvovaginal Candidiasis

Jul 10 2018, 4:05 PM EDT

## SCYNEXIS Announces the Presentation of SCY-078 Data at the Teratology Society 58th Annual Meeting

Jun 27 2018, 8:00 AM EDT

## Stock Overview

Symbol	SCYX
Exchange	Nasdaq
Shares OS	28,558,957
Market Cap	\$52.55M
Last Price	\$1.84
52-Week	\$1.05 - \$2.50

07/20/2018 04:00 PM EDT

## Investor Relations

Argot Partners  
Natalie Wildenradt  
T: 212-600-1902  
[natalie@argotpartners.com](mailto:natalie@argotpartners.com)

## Leadership

### Marco Taglietti, M.D.

President and Chief Executive Officer

### David Angulo, M.D.

Chief Medical Officer

### Eric Francois

Chief Financial Officer

### Scott Sukenick

General Counsel

## SCYNEXIS, Inc.

1 Evertrust Plaza  
13th Floor  
Jersey City, NJ 07302

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.